论文部分内容阅读
目的探讨肝动脉化疗栓塞(TACE)同期联合射频消融(RFA)治疗原发性肝癌的安全性与有效性。方法 13例原发性肝癌患者,共有17个肿瘤病灶,均于TACE术后3-20d内,同期联合CT导引下RFA治疗,以增强MR随访复查,观察肿瘤的消融率以及复发情况。结果 13例患者均耐受TACE同期联合RFA治疗,术后1个月肿瘤完全消融率为88.2%(15/17),随访2-14个月,1例术后7个月出现新发病灶,1例术后12个月出现局部病灶进展,余9例患者病灶稳定,肿瘤局部控制率为81.8%(9/11),1年内的肿瘤复发率为18.2%(2/11),13例患者中1例因上消化道出血死亡,1例改用外科手术切除后失访,余均存活,总生存率84.6%(11/13)。结论采用TACE同期联合RFA治疗,是一种安全有效的治疗方法。
Objective To investigate the safety and efficacy of simultaneous hepatic artery chemoembolization (TACE) and radiofrequency ablation (RFA) in the treatment of primary liver cancer. Methods Thirteen patients with primary hepatocellular carcinoma (HCC) had a total of 17 tumor lesions. All of them were treated with RFA within 3-20 days after TACE combined with CT-guided RFA to enhance the follow-up of MR. The ablation rate and relapse rate were observed. Results Thirteen patients were both treated with concurrent TACE and RFA. The complete tumor ablation rate was 88.2% (15/17) at 1 month after operation. The patients were followed up for 2-14 months. One case developed new lesions at 7 months after operation, One case had local lesion progressing at 12 months after operation, and the other 9 cases were stable with local control rate of 81.8% (9/11) and 18.2% (2/11) in 1 year. Thirteen patients One case died of upper gastrointestinal bleeding, one case was surgically removed and then lost. All survived, the overall survival rate was 84.6% (11/13). Conclusions TACE combined with RFA treatment is a safe and effective treatment.